Consistent with these observations, hyperactivation of mTORC1 is associated with resistance to HER2-targeted therapies, and combining mTORC1 inhibitors with HER2 inhibitors can restore drug sensitivity in resistant cancers [113]. Here, ERBB2 is linked to cancer.